| P50 | author | Yukie Takabatake | Q59692005 |
| | Robert Z Orlowski | Q91428664 |
| P2093 | author name string | Shuang Chen | |
| | Steven Grant | |
| | Yun Dai | |
| | Liang Zhou | |
| | Michael W Sanderson | |
| | Xin-Yan Pei | |
| | Lora B Kramer | |
| | Jessica Felthousen | |
| | Leena E Youssefian | |
| | Wesley W Bodie | |
| P2860 | cites work | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins | Q24302494 |
| | ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL | Q24306894 |
| | Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 | Q28256819 |
| | Thr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancer | Q28484291 |
| | Mitochondrial membrane permeabilization in cell death | Q29547425 |
| | Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 |
| | Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors | Q30424831 |
| | Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage | Q31160033 |
| | FoxM1 is a general target for proteasome inhibitors | Q33492774 |
| | Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. | Q34017354 |
| | Small molecule modulators of cyclin-dependent kinases for cancer therapy | Q34293568 |
| | Mcl-1: a highly regulated cell death and survival controller | Q34491222 |
| | Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo | Q34667764 |
| | Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway | Q44588841 |
| | Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events | Q44795441 |
| | Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 |
| | Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. | Q45197519 |
| | IL-6-independent expression of Mcl-1 in human multiple myeloma | Q48010145 |
| | Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. | Q52546411 |
| | The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak | Q57279398 |
| | Nonionic detergents induce dimerization among members of the Bcl-2 family | Q73343305 |
| | Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression | Q78634781 |
| | Management of relapsed and relapsed/refractory multiple myeloma | Q85048468 |
| | Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells | Q35153790 |
| | Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death | Q35567260 |
| | Mcl-1 regulation and its role in multiple myeloma | Q35910365 |
| | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis | Q35989478 |
| | MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism | Q35990714 |
| | Targeting multiple myeloma cells and their bone marrow microenvironment | Q36009239 |
| | Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo | Q36162685 |
| | CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies | Q36170136 |
| | Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis | Q36288687 |
| | Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. | Q36333522 |
| | Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma | Q36367811 |
| | The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions | Q36501937 |
| | A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells | Q36675950 |
| | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex | Q36706340 |
| | Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. | Q36767790 |
| | Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells | Q36868759 |
| | Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | Q36889961 |
| | Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels | Q36946423 |
| | Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. | Q37207049 |
| | Latest advances and current challenges in the treatment of multiple myeloma | Q37986287 |
| | Emerging strategies for targeting cell adhesion in multiple myeloma | Q38041724 |
| | Bone marrow microenvironment in multiple myeloma progression. | Q38055141 |
| | Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells | Q38828546 |
| | Molecular mechanisms of acquired proteasome inhibitor resistance | Q39278628 |
| | Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells | Q39360515 |
| | Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor | Q39407551 |
| | Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition | Q39435523 |
| | ARC synergizes with ABT-737 to induce apoptosis in human cancer cells | Q39697805 |
| | Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma | Q40124624 |
| | Cell-cell contact mediated signalling - no fear of contact. | Q40292594 |
| | Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation | Q40383692 |
| | Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. | Q40420617 |
| | VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis | Q40541706 |
| | The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase | Q40552228 |
| | Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover | Q40606380 |
| | Myeloid cell factor-1 is a critical survival factor for multiple myeloma | Q40655990 |
| | Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors | Q41907705 |
| | Shifting the balance of mitochondrial apoptosis: therapeutic perspectives | Q42474267 |
| | Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines | Q42534915 |
| | Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism | Q44182944 |
| | Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms | Q44452179 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| | multiple drug resistance | Q643839 |
| | drug resistance | Q12147416 |
| P304 | page(s) | e89064 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells | |
| P478 | volume | 9 | |